These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 20024612)

  • 41. The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.
    Hu Y; Mintz A; Shah SR; Quinones-Hinojosa A; Hsu W
    Carcinogenesis; 2014 Jul; 35(7):1491-9. PubMed ID: 24445144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
    Gong J; Gan J; Masson E; Syed S; Xia YQ; Williams D; Pursley J; Jemal M; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2012 Dec; 40(12):2374-80. PubMed ID: 22983304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
    El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
    Pearson A; Smyth E; Babina IS; Herrera-Abreu MT; Tarazona N; Peckitt C; Kilgour E; Smith NR; Geh C; Rooney C; Cutts R; Campbell J; Ning J; Fenwick K; Swain A; Brown G; Chua S; Thomas A; Johnston SRD; Ajaz M; Sumpter K; Gillbanks A; Watkins D; Chau I; Popat S; Cunningham D; Turner NC
    Cancer Discov; 2016 Aug; 6(8):838-851. PubMed ID: 27179038
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
    Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
    Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
    [No Abstract]   [Full Text] [Related]  

  • 47. Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics.
    Katoh M
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1375-9. PubMed ID: 20836672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.
    Ling L; Tan SK; Goh TH; Cheung E; Nurcombe V; van Wijnen AJ; Cool SM
    Mol Cancer; 2015 Jul; 14():136. PubMed ID: 26201468
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1.
    Ren M; Hong M; Liu G; Wang H; Patel V; Biddinger P; Silva J; Cowell J; Hao Z
    Oncol Rep; 2013 Jun; 29(6):2181-90. PubMed ID: 23563700
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth.
    Liu Z; Neiss N; Zhou S; Henne-Bruns D; Korc M; Bachem M; Kornmann M
    Cancer Res; 2007 Mar; 67(6):2712-9. PubMed ID: 17363592
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma.
    Lehnen NC; von Mässenhausen A; Kalthoff H; Zhou H; Glowka T; Schütte U; Höller T; Riesner K; Boehm D; Merkelbach-Bruse S; Kirfel J; Perner S; Gütgemann I
    Histopathology; 2013 Aug; 63(2):157-66. PubMed ID: 23808822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
    Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA
    Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FGFR antagonist induces protective autophagy in FGFR1-amplified breast cancer cell.
    Chen Y; Xie X; Li X; Wang P; Jing Q; Yue J; Liu Y; Cheng Z; Li J; Song H; Li G; Liu R; Wang J
    Biochem Biophys Res Commun; 2016 May; 474(1):1-7. PubMed ID: 26993162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
    Malchers F; Dietlein F; Schöttle J; Lu X; Nogova L; Albus K; Fernandez-Cuesta L; Heuckmann JM; Gautschi O; Diebold J; Plenker D; Gardizi M; Scheffler M; Bos M; Seidel D; Leenders F; Richters A; Peifer M; Florin A; Mainkar PS; Karre N; Chandrasekhar S; George J; Silling S; Rauh D; Zander T; Ullrich RT; Reinhardt HC; Ringeisen F; Büttner R; Heukamp LC; Wolf J; Thomas RK
    Cancer Discov; 2014 Feb; 4(2):246-57. PubMed ID: 24302556
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recurrent amplification in the 22q11 region in laryngeal squamous cell carcinoma results in overexpression of the CRKL but not the MAPK1 oncogene.
    Kostrzewska-Poczekaj M; Giefing M; Jarmuz M; Brauze D; Pelinska K; Grenman R; Bartochowska A; Szyfter W; Szyfter K
    Cancer Biomark; 2010-2011; 8(1):11-9. PubMed ID: 21896986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anti-tumour activity of 4-(4-fluorophenyl)amino-5,6,7-trimethoxyquinazoline against tumour cells in vitro.
    Huang Y; Liu F; Zhao L; Wu H; Liu H
    Cell Biol Int; 2012 Apr; 36(4):377-82. PubMed ID: 22073964
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
    Dempke WC; Zippel R
    Anticancer Res; 2010 Nov; 30(11):4477-83. PubMed ID: 21115896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Canine and human sarcomas exhibit predominant FGFR1 expression and impaired viability after inhibition of signaling.
    Schweiger N; Hauck M; Steinhoff H; Sampl S; Reifinger M; Walter I; Kreilmeier T; Marian B; Grusch M; Berger W; Holzmann K; Kleiter M
    Mol Carcinog; 2015 Sep; 54(9):841-52. PubMed ID: 24719266
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Syndecan-4 is required for thrombin-induced migration and proliferation in human vascular smooth muscle cells.
    Rauch BH; Millette E; Kenagy RD; Daum G; Fischer JW; Clowes AW
    J Biol Chem; 2005 Apr; 280(17):17507-11. PubMed ID: 15731100
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
    Chi F; Griffiths JI; Nath A; Bild AH
    Breast Cancer Res; 2024 Mar; 26(1):54. PubMed ID: 38553760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.